Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853138)
Watch
English
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
25733882
retrieved
13 November 2016
title
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
(English)
1 reference
stated in
PubMed
PubMed ID
25733882
retrieved
13 November 2016
main subject
lorlatinib
1 reference
stated in
ChEBI release 2020-05-28
ChEBI ID
143117
crizotinib
1 reference
based on heuristic
inferred from title
author name string
Helen Y Zou
series ordinal
1
0 references
Qiuhua Li
series ordinal
2
0 references
Lars D Engstrom
series ordinal
3
0 references
Melissa West
series ordinal
4
0 references
Vicky Appleman
series ordinal
5
0 references
Katy A Wong
series ordinal
6
0 references
Michele McTigue
series ordinal
7
0 references
Ya-Li Deng
series ordinal
8
0 references
Wei Liu
series ordinal
9
0 references
Alexei Brooun
series ordinal
10
0 references
Sergei Timofeevski
series ordinal
11
0 references
Scott R P McDonnell
series ordinal
12
0 references
Ping Jiang
series ordinal
13
0 references
Matthew D Falk
series ordinal
14
0 references
Patrick B Lappin
series ordinal
15
0 references
Timothy Affolter
series ordinal
16
0 references
Tim Nichols
series ordinal
17
0 references
Wenyue Hu
series ordinal
18
0 references
Justine Lam
series ordinal
19
0 references
Ted W Johnson
series ordinal
20
0 references
Tod Smeal
series ordinal
21
0 references
Al Charest
series ordinal
22
0 references
Valeria R Fantin
series ordinal
23
0 references
language of work or name
English
0 references
publication date
17 March 2015
0 references
published in
Proceedings of the National Academy of Sciences of the United States of America
0 references
volume
112
0 references
issue
11
0 references
page(s)
3493-8
0 references
cites work
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Q27690215
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
ROS1 rearrangements define a unique molecular class of lung cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Characterization of ROS1 cDNA from a human glioblastoma cell line
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
The protein tyrosine kinase family of the human genome
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
20 March 2017
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
7 April 2017
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
7 April 2017
Diversity of gene expression in adenocarcinoma of the lung
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
7 April 2017
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
7 April 2017
The landscape of kinase fusions in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
ALK in lung cancer: past, present, and future
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
The transcriptional landscape and mutational profile of lung adenocarcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
RET, ROS1 and ALK fusions in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Diversity of mechanism-based pharmacodynamic models
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
29 September 2017
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
2 June 2018
Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
2 June 2018
A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371934
retrieved
2 June 2018
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1073%2FPNAS.1420785112
retrieved
21 January 2018
Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1073%2FPNAS.1420785112
retrieved
21 January 2018
Identifiers
DOI
10.1073/PNAS.1420785112
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560064
ADS bibcode
2015PNAS..112.3493Z
0 references
OpenCitations bibliographic resource ID
560064
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560064
PMCID
4371934
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560064
PubMed ID
25733882
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560064
ResearchGate publication ID
273156362
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
